SCHEMBL1616433

SCHEMBL1616433

c1ccc2c(c1)CC[C@H]2Nc1ccc2c(NCc3cc[nH]n3)cccc2n1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 1/20 0.39
PARP1 P09874 2/20 0.37
HDAC6 Q9UBN7 1/20 0.37
KCNN3 Q9UGI6 1/20 0.37
PFKFB3 Q16875 1/20 0.36
EGFR P00533 1/20 0.36
FADS1 O60427 1/20 0.35
DDB1 Q16531 1/20 0.35
CRBN Q96SW2 1/20 0.35
P2RX7 Q99572 2/20 0.35
TRPV1 Q8NER1 1/20 0.35
AURKA O14965 1/20 0.35
RPS6KB1 P23443 1/20 0.35
JAK2 O60674 2/20 0.35
JAK3 P52333 2/20 0.35
JAK1 P23458 1/20 0.35
TYK2 P29597 1/20 0.35
NAE1 Q13564 1/20 0.34
UBA3 Q8TBC4 1/20 0.34
PDPK1 O15530 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1616286 0.84 PFKFB3 (0.37) GBA1PARP1HDAC6KCNN3PFKFB3
SCHEMBL1616564 0.84 TAAR1 (0.40) GBA1PARP1HDAC6KCNN3EGFR
SCHEMBL1615636 0.83 NTRK1 (0.39) GBA1PARP1PFKFB3EGFRFADS1
SCHEMBL1616589 0.83 GBA1 (0.50) GBA1EGFRTRPV1JAK2JAK3
SCHEMBL1615739 0.83 ADRA1A (0.44) GBA1PARP1HDAC6KCNN3TRPV1
SCHEMBL1616104 0.82 HDAC6 (0.38) GBA1PARP1HDAC6KCNN3FADS1
SCHEMBL1616340 0.81 PDE10A (0.41) GBA1PFKFB3P2RX7TRPV1JAK2
SCHEMBL3844986 0.80 PDPK1 (0.47) GBA1HDAC6KCNN3PFKFB3EGFR
SCHEMBL1616542 0.79 GBA1 (0.40) GBA1PFKFB3EGFRFADS1P2RX7
SCHEMBL2248366 0.78 GBA1 (0.39) GBA1PARP1HDAC6KCNN3PFKFB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7923561-B2 Quinolines HOFFMANN-LA ROCHE INC. (US) 2011-04-12 US claimed
US-20080146567-A1 QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-19 US claimed
US-7923561-B2 Quinolines HOFFMANN-LA ROCHE INC. (US) 2011-04-12 US disclosed
EP-2099763-B1 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS HOFFMANN LA ROCHE (CH) 2010-08-11 EP disclosed
EP-2099763-A1 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS F.HOFFMANN-LA ROCHE AG (CH) 2009-09-16 EP disclosed
US-20080146567-A1 QUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2008-06-19 US disclosed
WO-2008068157-A1 2-AMINOQUINOLINES AS 5-HT(5A) RECEPTOR ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146567-A1 QUINOLINES HTR5A, HTR2B, HTR2C GBA1 662/4885PARP1 1138/4885HDAC6 852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.